title: Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
abstract: Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.
authors.affiliation: Department of Dermatology, Venerology, and Dermatooncology, Semmelweis University, Budapest, Hungary. b.horvath@derm.umcg.nl
authors.forename: Barbara
authors.initials: B
authors.lastname: Horváth
authors.forename: Judit
authors.initials: J
authors.lastname: Demeter
authors.forename: Nóra
authors.initials: N
authors.lastname: Eros
authors.forename: Judit
authors.initials: J
authors.lastname: Hársing
authors.forename: Judit
authors.initials: J
authors.lastname: Csomor
authors.forename: András
authors.initials: A
authors.lastname: Matolcsy
authors.forename: Gyula
authors.initials: G
authors.lastname: Bottlik
authors.forename: Gabriella
authors.initials: G
authors.lastname: Gyori
authors.forename: Márta
authors.initials: M
authors.lastname: Marschalkó
authors.forename: Sarolta
authors.initials: S
authors.lastname: Kárpáti
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D012867:Skin / Q000098:blood supply*; D050151:Subcutaneous Fat / Q000098:blood supply; D019043:Vascular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone